Candel Therapeutics, Inc. cash flow statement

In fiscal 2022, Candel Therapeutics, Inc.'s operations generated −$31.4m of cash; it spent $1.3m on capital projects, leaving free cash flow of −$32.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Candel Therapeutics, Inc.: cash flow statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Cash from operations	−9	−22	−31
Depreciation and amortisation	0	0	1
Stock-based pay	2	3	2
Capital spending	1	2	1
Free cash flow	−11	−24	−33
Free cash flow after stock pay	−13	−27	−35

US$ millions unless shown otherwise. Fiscal quarters.

Candel Therapeutics, Inc.: cash flow statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Cash from operations	−6	−4	−7	−5	−8	−7	−9	−7
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	0	1	2	−0	0	0	1	1
Capital spending	0	1	0	1	0	1	0	0
Free cash flow	−6	−5	−7	−6	−8	−8	−10	−7
Free cash flow after stock pay	−6	−6	−9	−5	−9	−8	−10	−8

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Candel Therapeutics, Inc.